1. Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome.
- Author
-
Maddison P, Gozzard P, Sadalage G, Ambrose PA, Chapman CJ, Murray A, Thomsen S, Berretta A, and Lang B
- Subjects
- Adult, Aged, Aged, 80 and over, Autoantibodies immunology, Autoantigens immunology, Female, Humans, Lambert-Eaton Myasthenic Syndrome immunology, Lung Neoplasms complications, Lung Neoplasms diagnosis, Male, Middle Aged, Neurons immunology, Small Cell Lung Carcinoma complications, Small Cell Lung Carcinoma diagnosis, Autoantibodies blood, Biomarkers, Tumor blood, Lambert-Eaton Myasthenic Syndrome complications, Lung Neoplasms immunology, Small Cell Lung Carcinoma immunology
- Abstract
Since approximately 50% of patients with Lambert-Eaton myasthenic syndrome (LEMS) subsequently develop small-cell lung cancer (SCLC), it is important to be able to predict cancer occurrence in these patients at neurological presentation. We aimed to determine whether circulating biomarkers were effective and objective predictors of cancer development in LEMS. We found that the presence of either SOX2, N-type voltage gated calcium channel or GABAb antibodies at LEMS diagnosis was highly sensitive (84%) and specific (87%) for the detection of SCLC. Screening for SOX2 and neuronal antibodies is a useful adjunct to clinical predictive scoring tools in predicting SCLC in LEMS., Competing Interests: Declaration of Competing Interest Bethan Lang is a co-applicant and receives royalties on patent application WO/2010/046716 entitled ‘Neurological Autoimmune Disorders’. The patent has been licensed to Euroimmun AG for the development of assays for LGI1 and other VGKC-complex antibodies., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF